Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology
Dandan Zhao,Xiaoxiao Zhang,Yuhui Tang,Peilin Guo,Rong Ai,Mengmeng Hou,Yiqi Wang,Xiwei Yuan,Luyao Cui,Yuguo Zhang,Suxian Zhao,Wencong Li,Yang Wang,Xiaoye Sun,Lingdi Liu,Shiming Dong,Lu Li,Wen Zhao,Yuemin Nan
DOI: https://doi.org/10.2147/JHC.S357380
2022-05-10
Journal of Hepatocellular Carcinoma
Abstract:Dandan Zhao, 1, 2 Xiaoxiao Zhang, 1, 2 Yuhui Tang, 1, 2 Peilin Guo, 1, 2 Rong Ai, 1, 2 Mengmeng Hou, 1, 2 Yiqi Wang, 1, 2 Xiwei Yuan, 1, 2 Luyao Cui, 1, 2 Yuguo Zhang, 1, 2 Suxian Zhao, 1, 2 Wencong Li, 1, 2 Yang Wang, 1, 2 Xiaoye Sun, 1, 2 Lingdi Liu, 1, 2 Shiming Dong, 1, 2 Lu Li, 1, 2 Wen Zhao, 1, 2 Yuemin Nan 1, 2 1 Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China; 2 Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, Shijiazhuang, Hebei, People's Republic of China Correspondence: Yuemin Nan, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, No. 139 Ziqiang Road, Shijiazhuang, Hebei Province, 050051, People's Republic of China, Tel +86 311-66781227, Fax +86 311-66781289, Email Purpose: The aim of this study was to identify and validate novel biomarkers for distinguishing among hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), liver fibrosis/liver cirrhosis (LF/LC) and chronic hepatitis B (CHB). Patients and Methods: Transcriptomic sequencing was conducted on the liver tissues of 5 patients with HCC, 5 patients with LF/LC, 5 patients with CHB, and 4 healthy controls. The expression levels of selected mRNAs and proteins were assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical (IHC) staining, and were verified in validation set (n=200) and testing set (n=400) via enzyme-linked immunosorbent assay (ELISA). Results: A total of 9 hub mRNAs were identified by short time-series expression miner and weighted gene co-expression network analysis. Of note, the results of qRT-PCR and IHC staining demonstrated that SHC adaptor protein 1 (SHC1), SLAM family member 8 (SLAMF8), and interleukin-32 (IL-32) exhibited gradually increasing trends in the four groups. Subsequent ELISA tests on the validation cohort indicated that the plasma levels of SHC1, SLAMF8 and IL-32 also gradually increased. Furthermore, a diagnostic model APFSSI (age, PLT, ferritin, SHC1, SLAMF8 and IL-32) was established to distinguish among CHB, LF/LC and HCC. The performance of APFSSI model for discriminating CHB from healthy subjects (AUC=0.966) was much greater compared to SHC1 (AUC=0.900), SLAMF8 (AUC=0.744) and IL-32 (AUC=0.821). When distinguishing LF/LC from CHB, APFSSI was the most outstanding diagnostic parameter (AUC=0.924), which was superior to SHC1, SLAMF8 and IL-32 (AUC=0.812, 0.684 and 0.741, respectively). Likewise, APFSSI model with the greatest AUC value displayed an excellent performance for differentiating between HCC and LF/LC than other variables (SHC1, SLAMF8 and IL-32) via ROC analysis. Finally, the results in the test set were consistent with those in the validation set. Conclusion: SHC1, SLAMF8 and IL-32 can differentiate among patients with HCC, LF/LC, CHB and healthy controls. More importantly, the APFSSI model greatly improves the diagnostic accuracy of HBV-associated liver diseases. Keywords: HBV-associated liver diseases, transcriptome sequencing technology, SHC adaptor protein 1, SLAM family member 8, interleukin-32 Hepatitis B virus (HBV) infection is a global health issues, especially in developing countries, which affects 257 million people and causes 887,000 deaths annually. 1 The three main stages in the progression of HBV infection are hepatocellular carcinoma (HCC), liver fibrosis/liver cirrhosis (LF/LC) and chronic hepatitis B (CHB), or widely recognized as "hepatitis trilogy". 2 CHB is commonly known for the heterogeneous patient features and long course of disease progression, 3 while LF is a wound healing process. Both are necessary stages for the progression from chronic liver disease to cirrhosis, and even HCC. 4 Despite great advancements in diagnosis and treatment, the majority of HCC patients have unfavorable outcomes, with a 5-year overall survival rate of <50%. 5 Thus, it is of great importance to identify at-risk patients for early management of this disease. 6 Currently, there are few specific clinical non-invasive diagnostic methods for HBV-related liver diseases. The gold standard for diagnosing LF or liver cancer still underlies a tissue pathology-based approach, which is known as an invasive procedure with potential risks or -Abstract Truncated-
oncology